-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Yesterday, Orsondor Medical announced the establishment of its second wholly-owned subsidiary, Orsondor Biotechnology Development (Shanghai) Co.
, Ltd.
, and the Orsondor Biotechnology Innovation Center was officially listed in Shanghai Pudong Waigaoqiao Free Trade Zone.
Ms.
Lin Yan, President of Orsondor Medical Greater China, Deputy Director of the Management Committee of China (Shanghai) Pilot Free Trade Zone and Deputy Director of Free Trade Zone Administration Chen Yanfeng, President of the Application Evaluation Branch of the Chinese Medical Equipment Association, and Medical Engineering Branch of the Chinese Medical Association Professor Cai Kui, Vice Chairman, Professor Wang Hualiang, President of Shanghai Institute of Experimental Medicine, Director of Shanghai Clinical Laboratory Center, Chairman of Experimental Medicine Branch of National Health Industry Enterprise Management Association, Vice President of Shanghai Institute of Experimental Medicine, National Health Industry Professor Song Haibo, the vice president of the Enterprise Management Association, the president of the Medical Inspection Industry Branch, the editor-in-chief of WILEY’s VIEW journal, and local city supervisors, taxation, customs, and leaders of the Waigaoqiao Group Company at all levels came to the site to unveil the center.
At the same time, Runda Medical’s deputy General Manager Hu Zhenning and Kaishi Biologics General Manager Wang Dong attended as special guests to witness Orsondor's full launch of localized innovation and help China create a new chapter in the global market.
The biotechnology innovation center unveiled this time will focus on technology development and services in the fields of biotechnology and medical devices.
It is an important measure for Orson to integrate global innovation resources and fully initiate localized innovation.
Professor Cai Kui, Chairman of the Applied Evaluation Branch of the Chinese Medical Equipment Association, mentioned: “In recent years, under the development concept of modern laboratory science, the importance of in vitro diagnostics has been increasing, but with the increasing degree of aging of the population The clinic also puts forward higher requirements for testing technology and medical devices.
Contemporary in vitro diagnostic companies not only need to fully understand the clinical and patient needs, so that testing can become a solid backing for clinical decision-making; at the same time, they also need to have considerable scientific research spirit and innovative capabilities.
Ms.
Lin Yan, President of Orcendor Medical Greater China, said: "The Chinese market is a crucial part of Orcendor's global innovation layout.
With the in-depth advancement of the Healthy China 2030 strategy, a series of reform policies are piloted in the Waigaoqiao Free Trade Zone to provide policy support and reform assistance for biomedical companies.
For example, in 2017, the medical device registrant system was piloted for the first time in the Shanghai Free Trade Zone.
Through the establishment of this biotechnology innovation center, Orson Medical will gradually establish a global R&D and production supply chain including China and the Asia-Pacific region to better serve the Chinese diagnostic market.
(Sina Pharmaceutical News)
Yesterday, Orsondor Medical announced the establishment of its second wholly-owned subsidiary, Orsondor Biotechnology Development (Shanghai) Co.
, Ltd.
, and the Orsondor Biotechnology Innovation Center was officially listed in Shanghai Pudong Waigaoqiao Free Trade Zone.
Ms.
Lin Yan, President of Orsondor Medical Greater China, Deputy Director of the Management Committee of China (Shanghai) Pilot Free Trade Zone and Deputy Director of Free Trade Zone Administration Chen Yanfeng, President of the Application Evaluation Branch of the Chinese Medical Equipment Association, and Medical Engineering Branch of the Chinese Medical Association Professor Cai Kui, Vice Chairman, Professor Wang Hualiang, President of Shanghai Institute of Experimental Medicine, Director of Shanghai Clinical Laboratory Center, Chairman of Experimental Medicine Branch of National Health Industry Enterprise Management Association, Vice President of Shanghai Institute of Experimental Medicine, National Health Industry Professor Song Haibo, the vice president of the Enterprise Management Association, the president of the Medical Inspection Industry Branch, the editor-in-chief of WILEY’s VIEW journal, and local city supervisors, taxation, customs, and leaders of the Waigaoqiao Group Company at all levels came to the site to unveil the center.
At the same time, Runda Medical’s deputy General Manager Hu Zhenning and Kaishi Biologics General Manager Wang Dong attended as special guests to witness Orsondor's full launch of localized innovation and help China create a new chapter in the global market.
The biotechnology innovation center unveiled this time will focus on technology development and services in the fields of biotechnology and medical devices.
It is an important measure for Orson to integrate global innovation resources and fully initiate localized innovation.
Professor Cai Kui, Chairman of the Applied Evaluation Branch of the Chinese Medical Equipment Association, mentioned: “In recent years, under the development concept of modern laboratory science, the importance of in vitro diagnostics has been increasing, but with the increasing degree of aging of the population The clinic also puts forward higher requirements for testing technology and medical devices.
Contemporary in vitro diagnostic companies not only need to fully understand the clinical and patient needs, so that testing can become a solid backing for clinical decision-making; at the same time, they also need to have considerable scientific research spirit and innovative capabilities.
Ms.
Lin Yan, President of Orcendor Medical Greater China, said: "The Chinese market is a crucial part of Orcendor's global innovation layout.
With the in-depth advancement of the Healthy China 2030 strategy, a series of reform policies are piloted in the Waigaoqiao Free Trade Zone to provide policy support and reform assistance for biomedical companies.
For example, in 2017, the medical device registrant system was piloted for the first time in the Shanghai Free Trade Zone.
On July 7, 2020, the State Council issued the "Notice on Doing a Good Job in the Duplication and Promotion of the Sixth Batch of Pilot Free Trade Zone Reform Pilot Experiences", clarifying that medical device The registrant’s entrusted production model is replicated and promoted nationwide.
The "Measures for the Supervision and Administration of Medical Devices", which was launched in March 2021 and will be implemented in June, puts innovation into the focus of development, prioritizes the review and approval of innovative medical devices, and supports the clinical promotion and use of innovative medical devices.
It will also strengthen the protection of intellectual property rights of medical devices and improve the ability of independent innovation of medical devices.
Through the establishment of this biotechnology innovation center, Orson Medical will gradually establish a global R&D and production supply chain including China and the Asia-Pacific region to better serve the Chinese diagnostic market.
(Sina Pharmaceutical News)
